ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
JPY 2041.0
(-0.34%)
JPY 2041.0
(-0.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.5 Billion JPY | 27.27% |
| 2022 | 5.1 Billion JPY | 6.53% |
| 2021 | 4.79 Billion JPY | 32.83% |
| 2020 | 3.61 Billion JPY | 139.39% |
| 2019 | 1.5 Billion JPY | -15.47% |
| 2018 | 1.78 Billion JPY | -36.85% |
| 2017 | 2.82 Billion JPY | 57.47% |
| 2016 | 1.79 Billion JPY | 53.86% |
| 2015 | 1.16 Billion JPY | -17.36% |
| 2014 | 1.41 Billion JPY | 101.0% |
| 2013 | 702 Million JPY | -32.95% |
| 2012 | 1.04 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.58 Billion JPY | -9.61% |
| 2024 Q1 | 1.75 Billion JPY | 80.49% |
| 2023 FY | 6.5 Billion JPY | 27.27% |
| 2023 Q1 | 1.7 Billion JPY | 2443.28% |
| 2023 Q2 | 1.35 Billion JPY | -20.72% |
| 2023 Q3 | 2.47 Billion JPY | 82.9% |
| 2023 Q4 | 974 Million JPY | -60.58% |
| 2022 Q4 | 67 Million JPY | -96.9% |
| 2022 FY | 5.1 Billion JPY | 6.53% |
| 2022 Q3 | 2.16 Billion JPY | 77.94% |
| 2022 Q2 | 1.21 Billion JPY | -26.98% |
| 2022 Q1 | 1.66 Billion JPY | 1310.17% |
| 2021 Q3 | 2.02 Billion JPY | 37.51% |
| 2021 FY | 4.79 Billion JPY | 32.83% |
| 2021 Q4 | 118 Million JPY | -94.16% |
| 2021 Q2 | 1.46 Billion JPY | 23.65% |
| 2021 Q1 | 1.18 Billion JPY | 811.38% |
| 2020 Q3 | 1.83 Billion JPY | 74.88% |
| 2020 FY | 3.61 Billion JPY | 139.39% |
| 2020 Q1 | 899 Million JPY | 7015.38% |
| 2020 Q2 | 1.04 Billion JPY | 16.46% |
| 2020 Q4 | -167 Million JPY | -109.12% |
| 2019 Q2 | -92 Million JPY | -110.97% |
| 2019 Q3 | 774 Million JPY | 941.3% |
| 2019 Q4 | -13 Million JPY | -101.68% |
| 2019 Q1 | 839 Million JPY | 205.4% |
| 2019 FY | 1.5 Billion JPY | -15.47% |
| 2018 FY | 1.78 Billion JPY | -36.85% |
| 2018 Q4 | -796 Million JPY | -149.17% |
| 2018 Q3 | 1.61 Billion JPY | 727.52% |
| 2018 Q2 | -258 Million JPY | -121.16% |
| 2018 Q1 | 1.21 Billion JPY | 291.97% |
| 2017 FY | 2.82 Billion JPY | 57.47% |
| 2017 Q2 | 797 Million JPY | -26.0% |
| 2017 Q3 | 1.58 Billion JPY | 99.0% |
| 2017 Q4 | -635 Million JPY | -140.04% |
| 2017 Q1 | 1.07 Billion JPY | 688.52% |
| 2016 FY | 1.79 Billion JPY | 53.86% |
| 2016 Q1 | 463 Million JPY | 219.02% |
| 2016 Q2 | 871 Million JPY | 88.12% |
| 2016 Q3 | 643 Million JPY | -26.18% |
| 2016 Q4 | -183 Million JPY | -128.46% |
| 2015 Q4 | -389 Million JPY | -137.08% |
| 2015 Q3 | 1.04 Billion JPY | 285.66% |
| 2015 Q2 | 272 Million JPY | 16.24% |
| 2015 Q1 | 234 Million JPY | 148.55% |
| 2015 FY | 1.16 Billion JPY | -17.36% |
| 2014 Q3 | 821 Million JPY | 13.09% |
| 2014 Q1 | 346 Million JPY | 134.91% |
| 2014 FY | 1.41 Billion JPY | 101.0% |
| 2014 Q4 | -482 Million JPY | -158.71% |
| 2014 Q2 | 726 Million JPY | 109.83% |
| 2013 Q3 | 981 Million JPY | 1425.68% |
| 2013 Q1 | 786 Million JPY | 288.49% |
| 2013 Q2 | -74 Million JPY | -109.41% |
| 2013 FY | 702 Million JPY | -32.95% |
| 2013 Q4 | -991 Million JPY | -201.02% |
| 2012 FY | 1.04 Billion JPY | 0.0% |
| 2012 Q4 | -417 Million JPY | -150.55% |
| 2012 Q2 | 54 Million JPY | 0.0% |
| 2012 Q3 | 825 Million JPY | 1427.78% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | -27.127% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 96.964% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 101.835% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 96.209% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | 3424.621% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 79.29% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 31.672% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 87.83% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | -807.821% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 50.634% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | -12.011% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | -230.957% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | 1415.789% |
| Tsumura & Co. | 20.01 Billion JPY | 67.529% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | -61.812% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | -29.071% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 63.169% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | -68.481% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 33.104% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | -8.099% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 311.108% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | -66.923% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | 900.82% |
| MedRx Co., Ltd | -933 Million JPY | 796.677% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | -26.165% |
| Solasia Pharma K.K. | -1.13 Billion JPY | 670.676% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 374.262% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 65.583% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | 1031.984% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 66.375% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | -48.323% |